Showing 801-810 of 2298 results for "".
- Nanocatalytic Gold Treatment Improves Multiple Sclerosis Functional Composite Scores in Phase 2 Studieshttps://practicalneurology.com/news/nanocatalytic-gold-treatment-improves-multiple-sclerosis-functional-composite-scoresin-phase-2-studies/2469513/Treatment with the bioenergetic catalyst nanocrystalline gold (CNM-Au8; Clene Nanomedicine, Salt Lake City, UT) improved Multiple Sclerosis Functional Composite (MSFC) scores significantly more than placebo. Participants in the trial continued taking disease-modifying treatments approved for the
- FDA Advises More Clinical Data is Need for Potential ALS Stem Cell Treatmenthttps://practicalneurology.com/news/fda-advises-more-clinical-data-for-als-clinical-development-program/2469506/The Food and Drug Administration (FDA) gave feedback about autologous neurotrophic factor-secreting mesenchymal stem cells (MSC-NTF)(NurOwn; BrainStorm Cell Therapeutics, New York, NY), in a phase 3 clinical trial (
- Stem Cell Treatment Responses Fails to Reach Statistical Significance and Has High Placebo Response Ratehttps://practicalneurology.com/news/stem-cell-treatment-responses-fails-to-reach-statistical-significance-and-has-high-placebo-response-rate/2469434/In a phase 3 clinical trial (NCT03280056) of autologous neurotrophic factor-secreting mesenchymal stem cells (MSC-NTF)(NurOwn; BrainStorm Cell Therapeutics, New York, NY), 34.7% of participants wi
- Study Examining Ocrelizumab Treatment in African-Americans, Hispanic- and Latinx-Americans Is Actively Enrollinghttps://practicalneurology.com/news/study-examining-ocrelizumab-treatment-in-african-americans-hispanic-and-latinx-americans-is-actively-enrolling/2469376/A new study to characterize the response to ocrelizumab (Ocrevus; Genentech, South San Francisco, CHIMES (NCT04377555) in individuals from traditionally underrepresented groups was announced at MSVirtual2020 conference. This is the fir
- Phase 2 Clinical Trial for Stem-Cell Treatment of Alzheimer Disease Plannedhttps://practicalneurology.com/news/phase-2-clinical-trial-for-stem-cell-treatment-of-alzheimer-disease-planned/2469305/A phase 2 clinical trial to evaluate the safety and efficacy of treatment in individuals with prodromal to mild Alzheimer disease (AD) is planned for the autologous neurotrophic factor-secreting mesenchymal stem cell (MSC-NTF)(NurOwn; BrainStorm Cell Therapeutics, New York, NY). The program is be
- Verdiperstat, a Potential Treatment for Multiple System Atrophy, Granted Orphan Drug Statushttps://practicalneurology.com/news/verdiperstat-a-potential-treatment-for-multiple-system-atrophy-granted-orphan-drug-status/2468829/The Food and Drug Administration has granted orphan drug status to verdiperstat (BHV-3241; Biohaven Pharmaceutical, New Haven, CT). Verdiperstat is a novel brain-penetrant myeloperoxidase (MPO) inhibitor being studied as a potential first-in-class treatment for multiple system atrophy (MSA). Verd
- Novel Small Molecule PBT434 Receives Orphan Drug Designation for Treatment of Multiple System Atrophyhttps://practicalneurology.com/news/novel-small-molecule-pbt434-receives-orphan-drug-designation-for-treatment-of-multiple-system-atrophy/2468854/The Food and Drug Administration (FDA) has granted orphan drug designation for the molecule PBT434 (Prana Biotechnology LTD,Melbourne, Australia) as a potential treatment for multiple system atrophy (MSA) for which there are no approved therapies. The drug prevents iron-mediated protein aggregati
- Chris Ralyea, Jr, MBAhttps://practicalneurology.com/profiles/chris-ralyea-jr-mba/7ZBqQv/
- Thomas Patton, MDhttps://practicalneurology.com/profiles/thomas-patton-md/jJ3ykg/
- Dhishant Asarpota, MS, MBAhttps://practicalneurology.com/profiles/dhishant-asarpota-ms-mba/jQ4yVR/